1. Start with the disease and treatment history
CAR-T is not one interchangeable treatment. The first task is to identify the exact haematological malignancy or other approved disease context, confirm the pathology and biomarkers, and organise the prior lines of treatment. A product label for one disease, target, or treatment line cannot be carried across to another situation. This article is a navigation framework, not a diagnosis or an eligibility assessment.
2. Match the product, target, indication, and regulatory status
China has approved CAR-T products with different targets and tightly defined indications. For example, the reviewed NMPA pages for equecabtagene autoleucel and ciltacabtagene autoleucel describe BCMA-directed products for specified adults with relapsed or refractory multiple myeloma after defined prior treatment. Satri-cel has a separate, narrow solid-tumour indication. An approved product, an off-label proposal, an investigator-initiated study, and a registered trial are different pathways and should never be presented as equivalent.
3. Confirm the treating site and its current capability
A hospital profile, research publication, or historical trial role does not prove current international-patient acceptance or product supply. The treating site must confirm the named clinical team, product or protocol, collection and manufacturing pathway, admission arrangements, toxicity monitoring, intensive-care and rescue capability, interpreter access, and current scheduling. HarbourBridge profiles centres independently unless a written partnership is stated.
4. Obtain an itemised episode quotation
A product price is not the complete treatment episode. Written planning should separate pathology review, imaging and laboratory reassessment, leukapheresis, manufacturing, bridging treatment, lymphodepletion, infusion, admission, medicines, toxicity management, possible intensive care, extended stay, follow-up, travel, and companion costs. Insurance review is also separate: policy wording, pre-authorisation, direct settlement, exclusions, and patient liability need written confirmation.
5. Plan toxicity response and care after returning home
The pathway is incomplete without a named discharge and return-home plan. Before travel, the treating hospital and the patient's home team should clarify monitoring, emergency instructions, medicines, infection precautions, contact routes, the discharge packet, and who will receive the handover. These details can change by product, hospital, and date, so they must be reconfirmed for the actual case.
What this framework can and cannot do
These five checks help organise a safer enquiry. They do not predict response, determine candidacy, guarantee manufacturing, reserve a hospital place, establish a price, or confirm insurance cover. Those decisions belong to the licensed treating team, the provider, and the insurer using current records and written terms.